Brief: Phathom Pharmaceuticals Announces Vonoprazan NDA Submission For Non-Erosive Gerd
26/09/2023 13:08
Sept 26 (Reuters) - Phathom Pharmaceuticals Inc
PHAT.O :
* PHATHOM PHARMACEUTICALS ANNOUNCES VONOPRAZAN NDA
SUBMISSION FOR
NON-EROSIVE GERD
* PHATHOM PHARMACEUTICALS INC - FDA ACTION DATE FOR
NON-EROSIVE
GERD NDA EXPECTED IN Q3 OF 2024
* PHATHOM PHARMACEUTICALS INC - EXPECTS A 10-MONTH
REGULATORY
REVIEW AND IF APPROVED, ANTICIPATES A Q3 2024 U.S. LAUNCH FOR
VONOPRAZAN
Source text for Eikon: ID:nGNX5Fkmqc
Further company coverage: PHAT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phathom Pharmaceuticals
See all newsBrief: Phathom Pharma Provides Update On Litigation Filed By BDR Pharma Against FDA
Phathom Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Phathom Pharmaceuticals Q2 revenue beats on Voquezna prescription growth
Brief: Phathom Pharmaceuticals Q2 Net Income USD -17.582 Million
Phathom Pharmaceuticals Q1 revenue more than doubles, beats estimates